Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KIV-318 in Relapsed/Refractory Multiple Myeloma
NCT07726160Phase 1Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jul 2026
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KIV-318 in multiple myeloma (MM), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Dose limiting toxicity at 28 days and Treatment-emergent adverse events at 2 years. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
KIV-318
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07726160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07726160.